Charter Medical (LDL) Receives CE Mark Clearance for Next Generation Cell Freeze Cryogenic Stem Cell Storage

Charter Medical, Ltd., a Lydall subsidiary, (NYSE: LDL) announced today that it received CE Mark approval on its next generation Cell Freeze® Cryogenic Storage Containers for Hematopoietic Progenitor Cells (HPC's). The issuance of the approval by European regulators allows Charter Medical to begin marketing and selling the newly designed and expanded product offering for cryogenic storage, preservation, and transfer of HPC's in Europe. These next generation storage containers offer a broad size range from 50 mL to 750 mL and have excellent durability when frozen at ultralow (-196°C) temperatures.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders
• loanDepot receives NYSE non-compliance notice over stock price